BerGenBio Participation at Upcoming Healthcare Investor and Life Sciences Industry Conferences

Monday, May 14, 2018 Lifestyle News
Email Print This Page Comment bookmark
Font : A-A+

BERGEN, Norway, May 14, 2018 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing

novel, selective AXL kinase inhibitors for multiple cancer indications, will be participating at the following upcoming conferences.

  • 14-16 May, Bio€quity Europe 2018 (Ghent, Belgium)*
  • 23
    May, ABG Sundal Collier Cancer Seminar (Stockholm, Sweden)*
  • 1 June, Sachs Immuno-Oncology BD&L and Investment Forum (Chicago, IL)*
  • 4 June, Norne Securities Conference (Bergen, Norway)* 
  • 1-5 June, 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Chicago, IL)*† (more details to follow)
  • 4-7 June, BIO Annual Convention (Boston, MA
  • 5-8 June, Jefferies Global Healthcare Conference (New York, USA)

Further details can be found on BerGenBio's website (www.bergenbio.com) in the Media Centre / Events section.

*The slides and posters presented at these events will be made available on BerGenBio's website in the Investors / Presentations section following the presentations.

†BerGenBio will be hosting a reception on 2 June at The School of the Art Institute Ballroom, Chicago, USA during which short presentations will be given by clinical investigators participating in the bemcentinib clinical trials and key opinion leaders in AXL biology. For more information, please visit www.bergenbio.com/media-centre/events/.

About BerGenBio ASA 

BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors as a potential cornerstone of combination cancer therapy. The Company is a world leader in understanding the essential role of AXL kinase in mediating aggressive diseases, including immune evasive, drug resistance metastatic solid and haematological cancers.

BerGenBio's lead product, bemcentinib (BGB324), is a selective, potent and orally bio-available small molecule AXL inhibitor in four Company sponsored Phase II clinical trials in major cancer indications, with read-outs anticipated during 2018. It is the only selective AXL inhibitor in clinical development.

The Company sponsored clinical trials are:

  • Bemcentinib with TARCEVA® (erlotinib) in advanced EGFR mutation driven non-small cell lung cancer (NSCLC)
  • Bemcentinib with KEYTRUDA in advanced adenocarcinoma of the lung, and
  • Bemcentinib with KEYTRUDA in triple-negative breast cancer (TNBC).
  • Bemcentinib as a single agent and combination therapy in acute myeloid leukaemia (AML) / myeloid dysplastic syndrome (MDS)

The clinical trials combining bemcentinib with KEYTRUDA in adenocarcinoma of the lung and TNBC are conducted in collaboration with Merck & Co., Inc. (Kenilworth, NJ, USA), through a subsidiary.

In addition, a number of investigator-sponsored trials are underway, including a trial to investigate bemcentinib with either MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial combining bemcentinib with docetaxel in advanced NSCLC.

BerGenBio is simultaneously developing a companion diagnostic test to identify patient subpopulations most likely to benefit from treatment with bemcentinib. This will facilitate more efficient registration trials and support a precision medicine based commercialization strategy.

The Company is also developing a diversified pre-clinical pipeline of drug candidates, including BGB149, an anti-AXL monoclonal antibody.

For further information, please visit: www.bergenbio.com 

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a registered trademark of Novartis International AG and MEKINIST® is a registered trademark of GSK plc.

Contacts  Richard GodfreyCEO, BerGenBio ASA+47-917-86-304

Rune SkeieCFOBerGenBio ASArune.skeie@bergenbio.com+47-917-86-513

Media Relations in NorwayJan Petter StiffCrux Advisersstiff@crux.no+47-995-13-891

International Media RelationsDavid DibleMark SwallowMarine PerrierCitigate Dewe Rogersonbergenbio@citigatedewerogerson.com+44-207-638-9571

Forward looking statements 

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. 

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/bergenbio-asa/r/bergenbio-participation-at-upcoming-healthcare-investor-and-life-sciences-industry-conferences,c2519891

Cision View original content:http://www.prnewswire.com/news-releases/bergenbio-participation-at-upcoming-healthcare-investor-and-life-sciences-industry-conferences-300647540.html

SOURCE BerGenBio ASA

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store